You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ):九價HPV疫苗臨牀試驗相關工作仍在按計劃進行
格隆匯 05-12 07:42

格隆匯5月12日丨有投資者在投資者互動平台向沃森生物(300142.SZ)提問,“萬泰發起二價HPv疫苗與默沙東四價HPV頭對頭研究實驗。公司可否發起二價HPV預苗與萬泰二價頭對頭研究實驗?”

沃森生物回覆稱,公司九價HPV疫苗於2022年9月啟動了“重組人乳頭瘤病毒九價疫苗與 Gardasil 9 免疫原性比較Ⅲ期臨牀試驗”,正式進入Ⅲ期臨牀研究階段。目前,臨牀試驗相關工作仍在按計劃進行。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account